Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 30, 2026, 3:14 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 433–456 of 1,270 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Pathway Clear all
Terminated Phase 1 Interventional

RO4929097 and Erlotinib Hydrochloride in Treating Patients With Stage IV or Recurrent Non-small Cell Lung Cancer

NCT01193881
View directory record Official record
Conditions
Recurrent Non-Small Cell Lung Carcinoma, Stage IV Non-Small Cell Lung Cancer
Interventions
Erlotinib Hydrochloride, Gamma-Secretase Inhibitor RO4929097, Laboratory Biomarker Analysis, Pharmacological Study
Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2015
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Sep 29, 2015 · Synced Oct 30, 2026, 3:14 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Depression, Aging, Stress and Heart Health Study

NCT05570721
View directory record Official record
Conditions
Menopause, Depression, Heart Disease in Women, Stress
Interventions
Trier Social Stress Test
Behavioral
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
44 Years to 55 Years · Female only
Enrollment
41 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2025
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Oct 5, 2026 · Synced Oct 30, 2026, 3:14 AM EDT
Recruiting Phase 1Phase 2 Interventional

Study of AZD5863 in Adult Participants With Advanced or Metastatic Solid Tumors

NCT06005493
View directory record Official record
Conditions
Gastric Cancer, Gastro-esophageal Junction Cancer, Pancreatic Ductal Adenocarcinoma, Esophageal Adenocarcinoma
Interventions
AZD5863, AZD2936
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years and older
Enrollment
392 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2029
U.S. locations
3
States / cities
Jacksonville, Florida • Rochester, Minnesota • New York, New York
Source: ClinicalTrials.gov public record
Updated Sep 25, 2026 · Synced Oct 30, 2026, 3:14 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Paleolithic Diet and Exercise Study

NCT00360516
View directory record Official record
Conditions
Diet
Interventions
metabolic (nutrient controlled) diet
Behavioral
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years to 55 Years
Enrollment
10 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2007
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Jun 29, 2011 · Synced Oct 30, 2026, 3:14 AM EDT
Completed Not applicable Interventional Results available

Piloting Pathways With Lung Cancer Patients

NCT04161157
View directory record Official record
Conditions
Metastatic Lung Cancer
Interventions
Pathways
Behavioral
Lead sponsor
Laurie McLouth
Other
Eligibility
18 Years and older
Enrollment
53 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
1
States / cities
Lexington, Kentucky
Source: ClinicalTrials.gov public record
Updated Oct 5, 2023 · Synced Oct 30, 2026, 3:14 AM EDT
Active, not recruiting Phase 1 Interventional

A Study of JZP815 Oral Capsules in Adult Participants With Advanced or Metastatic Solid Tumors Harboring Mitogen Activated Protein Kinase (MAPK) Pathway Alterations to Investigate the Safety, Dosing, and Antitumor Activity of JZP815

NCT05557045
View directory record Official record
Conditions
Advanced Cancer, Metastatic Cancer, Solid Tumor, Melanoma, Non-small Cell Lung Cancer (NSCLC), Colorectal Cancer (CRC), Anaplastic Thyroid Cancer (ATC)
Interventions
JZP815
Drug
Lead sponsor
Jazz Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
98 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2028
U.S. locations
15
States / cities
Los Angeles, California • Denver, Colorado • Orlando, Florida + 10 more
Source: ClinicalTrials.gov public record
Updated Sep 10, 2026 · Synced Oct 30, 2026, 3:14 AM EDT
Completed Not applicable Interventional Results available

Assessing Inflammatory and Behavioral Pathways Linking PTSD to Increased Asthma Morbidity in WTC Workers

NCT04552301
View directory record Official record
Conditions
Asthma, PTSD
Interventions
Cognitive Processing Therapy, Psychotherapy, Targeted Asthma Education, General Asthma Education
Behavioral
Lead sponsor
Icahn School of Medicine at Mount Sinai
Other
Eligibility
18 Years and older
Enrollment
361 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Sep 19, 2024 · Synced Oct 30, 2026, 3:14 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

Study of PER977 Administered to Subjects With Steady State Edoxaban Dosing and Re-anticoagulation With Edoxaban

NCT02207257
View directory record Official record
Conditions
Anticoagulation Reversal
Interventions
PER977, Placebo, Edoxaban
Drug
Lead sponsor
Perosphere Pharmaceuticals Inc, a wholly owned subsidiary of AMAG Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
65 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2015
U.S. locations
1
States / cities
Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated May 21, 2020 · Synced Oct 30, 2026, 3:14 AM EDT
Completed Phase 2 Interventional Results available

MEK162 for Patients With RAS/RAF/MEK Activated Tumors

NCT01885195
View directory record Official record
Conditions
Solid Tumor and Hematologic Malignancies
Interventions
MEK162
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
110 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
68
States / cities
Mobile, Alabama • Anchorage, Alaska • Phoenix, Arizona + 57 more
Source: ClinicalTrials.gov public record
Updated Feb 21, 2021 · Synced Oct 30, 2026, 3:14 AM EDT
Terminated No phase listed Observational Accepts healthy volunteers

Mechanism of Weight Loss After Endoscopic and Laparoscopic Sleeve Procedures

NCT04006002
View directory record Official record
Conditions
Weight Loss, Reflux
Interventions
Metabolic and Hormonal profile
Other
Lead sponsor
Northwell Health
Other
Eligibility
18 Years to 75 Years
Enrollment
4 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2022
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Feb 14, 2022 · Synced Oct 30, 2026, 3:14 AM EDT
Not listed Not applicable Interventional Accepts healthy volunteers

Effectiveness of Two Different Entry Portal Pathways Into Primary Care for Musculoskeletal Injury

NCT02726802
View directory record Official record
Conditions
Physical Therapy Direct Access, Physical Therapy Primary Care
Interventions
physical therapy vs. primary care interventions
Other
Lead sponsor
Reynolds Army Community Hospital
Federal
Eligibility
18 Years and older
Enrollment
53 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2018
U.S. locations
1
States / cities
Fort Sill, Oklahoma
Source: ClinicalTrials.gov public record
Updated Nov 29, 2017 · Synced Oct 30, 2026, 3:14 AM EDT
Terminated Not applicable Interventional

Assessing Outcomes in ED Patients With RV Failure

NCT03073629
View directory record Official record
Conditions
Right Heart Failure
Interventions
Clinical Pathway
Diagnostic Test
Lead sponsor
Indiana University
Other
Eligibility
18 Years and older
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Jun 15, 2022 · Synced Oct 30, 2026, 3:14 AM EDT
Completed No phase listed Observational

Memantine XR and Pregabalin for Chemotherapy-Induced Peripheral Neuropathy

NCT03709888
View directory record Official record
Conditions
Chemotherapy-induced Peripheral Neuropathy
Interventions
Memantine XR-pregabalin combination therapy
Drug
Lead sponsor
Saint John's Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2021
U.S. locations
1
States / cities
Santa Monica, California
Source: ClinicalTrials.gov public record
Updated Apr 6, 2022 · Synced Oct 30, 2026, 3:14 AM EDT
Recruiting Phase 3 Interventional

A Rollover Extension Program (REP) to Evaluate the Long-term Safety and Tolerability of Open Label Iptacopan/LNP023 in Participants With Primary IgA Nephropathy

NCT04557462
View directory record Official record
Conditions
Primary IgA Nephropathy
Interventions
LNP023
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 100 Years
Enrollment
540 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2030
U.S. locations
16
States / cities
Glendale, Arizona • San Diego, California • San Dimas, California + 13 more
Source: ClinicalTrials.gov public record
Updated Oct 5, 2026 · Synced Oct 30, 2026, 3:14 AM EDT
Recruiting Phase 1 Interventional

Testing the Anti-cancer Drug, Cirtuvivint, and Its Combination With ASTX727 to Improve Outcomes in Patients With Acute Myeloid Leukemia and Myelodysplastic Syndromes

NCT06484062
View directory record Official record
Conditions
Acute Myeloid Leukemia, Myelodysplastic Syndrome, Myelodysplastic Syndrome/Acute Myeloid Leukemia, Recurrent Acute Myeloid Leukemia, Recurrent Myelodysplastic Syndrome, Recurrent Myelodysplastic Syndrome/Acute Myeloid Leukemia, Refractory Acute Myeloid Leukemia, Refractory Myelodysplastic Syndrome, Refractory Myelodysplastic Syndrome/Acute Myeloid Leukemia
Interventions
Biospecimen Collection, Bone Marrow Aspiration, Cirtuvivint, Decitabine and Cedazuridine, Echocardiography Test, Multigated Acquisition Scan
Procedure · Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
54 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
23
States / cities
New Haven, Connecticut • Atlanta, Georgia • Chicago, Illinois + 17 more
Source: ClinicalTrials.gov public record
Updated Oct 1, 2026 · Synced Oct 30, 2026, 3:14 AM EDT
Active, not recruiting Phase 2 Interventional

Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)

NCT02465060
View directory record Official record
Conditions
Advanced Lymphoma, Advanced Malignant Solid Neoplasm, Bladder Carcinoma, Breast Carcinoma, Cervical Carcinoma, Colon Carcinoma, Colorectal Carcinoma, Endometrial Carcinoma, Esophageal Carcinoma, Exocrine Pancreas Carcinoma, Gastric Carcinoma, Glioma, Head and Neck Carcinoma, Hematopoietic and Lymphoid Cell Neoplasm, Kidney Carcinoma, Liver Carcinoma, Lung Carcinoma, Lymphoma, Malignant Uterine Corpus Neoplasm, Malignant Uterine Neoplasm, Melanoma, Multiple Myeloma, Ovarian Carcinoma, Prostate Carcinoma, Rectal Carcinoma, Recurrent Bladder Carcinoma, Recurrent Breast Carcinoma, Recurrent Cervical Carcinoma, Recurrent Colon Carcinoma, Recurrent Colorectal Carcinoma, Recurrent Esophageal Carcinoma, Recurrent Gastric Carcinoma, Recurrent Glioma, Recurrent Head and Neck Carcinoma, Recurrent Liver Carcinoma, Recurrent Lung Carcinoma, Recurrent Lymphoma, Recurrent Malignant Solid Neoplasm, Recurrent Malignant Uterine Corpus Neoplasm, Recurrent Melanoma, Recurrent Multiple Myeloma, Recurrent Ovarian Carcinoma, Recurrent Pancreatic Carcinoma, Recurrent Prostate Carcinoma, Recurrent Rectal Carcinoma, Recurrent Skin Carcinoma, Recurrent Thyroid Gland Carcinoma, Refractory Lymphoma, Refractory Malignant Solid Neoplasm, Refractory Multiple Myeloma, Skin Carcinoma, Thyroid Gland Carcinoma
Interventions
Adavosertib, Afatinib, Afatinib Dimaleate, Binimetinib, Biopsy Procedure, Biospecimen Collection, Capivasertib, Computed Tomography, Copanlisib, Copanlisib Hydrochloride, Crizotinib, Cytology Specimen Collection Procedure, Dabrafenib, Dabrafenib Mesylate, Dasatinib, Defactinib, Defactinib Hydrochloride, Echocardiography Test, Erdafitinib, Fexagratinib, Ipatasertib, Laboratory Biomarker Analysis, Larotrectinib, Larotrectinib Sulfate, Magnetic Resonance Imaging, Multigated Acquisition Scan, Nivolumab, Osimertinib, Palbociclib, Pertuzumab, PI3K-beta Inhibitor GSK2636771, Radiologic Examination, Radionuclide Imaging, Relatlimab, Sapanisertib, Sunitinib Malate, Taselisib, Trametinib, Trastuzumab, Trastuzumab Emtansine, Ulixertinib, Vismodegib
Drug · Procedure · Other + 1 more
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
6,452 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2027
U.S. locations
1405
States / cities
Birmingham, Alabama • Fairhope, Alabama • Mobile, Alabama + 847 more
Source: ClinicalTrials.gov public record
Updated Oct 26, 2026 · Synced Oct 30, 2026, 3:14 AM EDT
Completed No phase listed Observational

Endoscopic Sleeve Gastroplasty / Endoscopic Sleeve Gastroplasty

NCT04640688
View directory record Official record
Conditions
Obesity
Interventions
Bariatric procedures
Procedure
Lead sponsor
Methodist Health System
Other
Eligibility
18 Years and older
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2026
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Mar 23, 2026 · Synced Oct 30, 2026, 3:14 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Biological Triggers of Depression in Pregnancy

NCT02566980
View directory record Official record
Conditions
Depression and Suicide, Mood Disorders, Other Perinatal Conditions
Interventions
Not listed
Lead sponsor
Michigan State University
Other
Eligibility
18 Years and older · Female only
Enrollment
209 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2017
U.S. locations
3
States / cities
Grand Rapids, Michigan
Source: ClinicalTrials.gov public record
Updated Jun 28, 2018 · Synced Oct 30, 2026, 3:14 AM EDT
Completed Not applicable Interventional Results available

Nano-Pulse Stimulation (NPS) in Sebaceous Hyperplasia

NCT03612570
View directory record Official record
Conditions
Skin Lesion, Skin Abnormalities, Sebaceous Hyperplasia
Interventions
Nano-Pulse Stimulation Device
Device
Lead sponsor
Pulse Biosciences, Inc.
Industry
Eligibility
18 Years to 70 Years
Enrollment
72 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018
U.S. locations
5
States / cities
Sacramento, California • San Mateo, California • Chestnut Hill, Massachusetts + 2 more
Source: ClinicalTrials.gov public record
Updated Apr 12, 2024 · Synced Oct 30, 2026, 3:14 AM EDT
Completed Not applicable Interventional

Effectiveness of BREG Flex in 12-week Peri-operative Total Knee Arthroplasty

NCT03840096
View directory record Official record
Conditions
Knee Osteoarthritis
Interventions
Breg Flex
Device
Lead sponsor
The Hawkins Foundation
Other
Eligibility
55 Years and older
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
2
States / cities
Greenville, South Carolina
Source: ClinicalTrials.gov public record
Updated Sep 9, 2021 · Synced Oct 30, 2026, 3:14 AM EDT
Completed Phase 1 Interventional

VNP40101M in Treating Young Patients With Recurrent, Progressive, or Refractory Primary Brain Tumors

NCT00098761
View directory record Official record
Conditions
Brain and Central Nervous System Tumors
Interventions
laromustine
Drug
Lead sponsor
Pediatric Brain Tumor Consortium
Network
Eligibility
Up to 21 Years
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2008
U.S. locations
10
States / cities
San Francisco, California • Washington D.C., District of Columbia • Chicago, Illinois + 7 more
Source: ClinicalTrials.gov public record
Updated Jun 30, 2011 · Synced Oct 30, 2026, 3:14 AM EDT
Completed Phase 3 Interventional Results available

Safety and Efficacy of Abaloparatide-SC in Men With Osteoporosis (ATOM)

NCT03512262
View directory record Official record
Conditions
Osteoporosis, Osteoporosis, Age-Related, Osteoporosis Localized to Spine, Age Related Osteoporosis, Osteoporosis Senile, Osteoporosis of Vertebrae
Interventions
Abaloparatide, Placebo
Drug
Lead sponsor
Radius Health, Inc.
Industry
Eligibility
40 Years to 85 Years · Male only
Enrollment
228 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
22
States / cities
Birmingham, Alabama • Greenbrae, California • Simi Valley, California + 18 more
Source: ClinicalTrials.gov public record
Updated Apr 7, 2023 · Synced Oct 30, 2026, 3:14 AM EDT
Completed Phase 2 Interventional

Temozolomide in Treating Patients With Progressive Low-Grade Glioma

NCT00003466
View directory record Official record
Conditions
Brain and Central Nervous System Tumors
Interventions
temozolomide
Drug
Lead sponsor
Duke University
Other
Eligibility
4 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1998 – 2005
U.S. locations
2
States / cities
Durham, North Carolina • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jul 9, 2014 · Synced Oct 30, 2026, 3:14 AM EDT
Active, not recruiting Not applicable Interventional

Continuous And Data-drivEN CarE (CADENCE) Pilot

NCT05609669
View directory record Official record
Conditions
Pregnancy Related, Opioid Use Disorder
Interventions
CADENCE program
Other
Lead sponsor
University of South Florida
Other
Eligibility
18 Years and older · Female only
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Nov 10, 2025 · Synced Oct 30, 2026, 3:14 AM EDT